Key session presented at the European Respiratory Society (ERS) International Congress 2022, 3rd-6th Sept. 2022, Barcelona.

A recent study concluded that early initiation of SGLT2i in people with preserved eGFR may provide kidney protection benefits. SGLT2i reduced risk of renal disease progression by 27% to 57% and HF outcomes by 13% to 32% for all eGFR categories, reported the study. Greatest risk reduction for HF outcomes was reported for lower eGFR values (eGFR <30 ml/min/1.73m2).

Findings from a recent study suggests higher risk of CVD, IHD, and mortality from all-cause in T2DM patients with disrupted CRAR. Decreased day-to-day consistency, robustness, or high fragmentation in circadian rest-activity rhythm may indicate higher risks of CVD and mortality in patients with T2DM, reported the study.